Categories: News

Innovaccer Announces Connected Digital Health Solution for Biopharma and Medtech

New solution will allow life sciences companies to realize the promise of digital health with holistic, “around-the-brand” experiences that connect brands, providers, and patients

SAN FRANCISCO–(BUSINESS WIRE)–Today Innovaccer, the Health Cloud company, announced its Connected Digital Health solution, a new way for life sciences companies to rapidly deliver next-generation digital apps that surround therapeutics and devices with highly engaging patient experiences, improve clinical outcomes, and generate valuable real world evidence (RWE).

With Innovaccer’s Connected Digital Health solution, biopharma and medtech companies will be able to speed time-to-market of patient-centric apps that connect patients to their care teams and deliver real-time health insights into their physicians’ workflows. Providers and patients alike will be able to act on these insights to improve care management and adherence, factors proven to enhance the quality of care.12

In addition, Innovaccer’s Connected Digital Health solution will enable patient- and population-level RWE to be generated and delivered to biopharma and medtech brands for indicating their real-world use, benefits, and potential target populations; identifying label expansion opportunities, supporting clinical trial designs and observational studies—ultimately providing crucial insights for further drug and device innovation.34

“Creating digital health apps with a unified brand-provider-patient workflow is the next great vista for pharma brands and we can help them cross it,” said Kanav Hasija, chief customer officer and cofounder of Innovaccer. “In an increasingly crowded market, launching another ‘me-too’ app isn’t enough for brands to succeed. Pharma brands must surround their products with ‘sticky’ experiences that exceed patients’ expectations when compared to the disconnected, point-solution apps patients typically ignore. With Innovaccer, pharma will be able to put an end to health app abandonment with connected health applications that patients really want to use.”

As a proven leader in value-based care and population health management, Innovaccer is ideally suited to help biopharma and medtech companies unlock the full value of their innovations by integrating them within care workflows, in partnership with providers and health plans. To date, Innovaccer has unified patient records for more than 39 million people across more than 1,600 care settings, including EHRs, labs, pharmacy, telehealth, remote care, devices, and more.

“Digital health app abandonment is a real problem for the industry,” says Abhinav Shashank, CEO and cofounder at Innovaccer. “There are over 350,000 digital health apps today, yet 83% were installed fewer than 5,000 times. They’re not compelling to patients because they work in isolation from the patient’s EHR, care team, and in many cases, the therapeutic brands themselves. We will change that by wrapping a brand-provider-patient workflow around the therapeutic or device that sends clinical insights into provider workflows, creating an end-to-end disease management system. Insights from digital apps will be actionable within the care workflow to everyone: the patient, the provider, and the pharma brand. Innovaccer’s Connected Digital Health solution represents the next generation of digital disease management.” 5

For more information on Innovaccer’s Connected Digital Health solution, please visit our digital solutions for biotech and medtech portals, or contact us at info@innovaccer.com.

About Innovaccer

Innovaccer Inc., the Health Cloud company, is dedicated to accelerating innovation in healthcare. The Innovaccer® Health Cloud unifies patient data across systems and care settings, and empowers healthcare organizations to develop scalable, modern applications that improve clinical, financial, and operational outcomes. Innovaccer’s solutions have been deployed across more than 1,600 care settings in the U.S., enabling more than 96,000 providers to transform care delivery and work collaboratively with payers and life sciences companies. Innovaccer has helped its customers unify health records for more than 39 million people and generate over $1B in cumulative cost savings. Innovaccer is the #1 rated Data and Analytics Platform by KLAS, and the #1 rated population health technology platform by Black Book. For more information, please visit innovaccer.com.

________________________________

1 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179865
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510928/#:~:text=Patients%20who%20are%20engaged%20in,factors%20that%20affect%20medication%20adherence
3 https://www.mckinsey.com/industries/life-sciences/our-insights/creating-value-from-next-generation-real-world-evidence
4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039945
5 https://www.medicaldevice-network.com/news/digital-health-apps

Contacts

Sachin Saxena

Innovaccer Inc.

sachin_saxena@innovaccer.com
415-504-3851

Staff

Recent Posts

Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani

* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…

17 hours ago

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

2 days ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

2 days ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

2 days ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

2 days ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

2 days ago